Thalassemia donor blood can no longer find a donor-www.97se.com

Thalassemia donor blood can no longer find a donor Nanfang Hospital developed haploidentical transplantation technique can also be used in the treatment of leukemia Huang Rongfang ready for the operation of the little girl. (picture) Guangzhou Daily reporter Su Junjie photo thalassemia children receive a transplant, don’t have to worry about can not find a donor! Yesterday morning, reporters from the South Hospital of Southern Medical University held a press conference was informed that the hospital research team with haploidentical transplantation, there will be related to patients "haploidentical donor" hematopoietic stem cells and unrelated donor cord blood "complementary transplantation", completely solve the transplantation of thalassemia for those problems, the cure rate of up to 96%. This technique is also applicable to the treatment of childhood leukemia and aplastic anemia. Anyone who has a relationship with a patient can become a donor.   the Guangzhou Daily reporter Huang Rongfang correspondent Li Xiaoshan before: 34 of patients can not find a suitable bone marrow donor   Nanfang Hospital of Southern Medical University Pediatrics director Li Chunfu introduction,   Mediterranean anemia (referred to as multiple thalassemia) along the coast of the Mediterranean countries in the Middle East, Central Asia and Southeast Asia, China, Guangxi and Hainan in Guangdong province the highest incidence of severe thalassemia, which required blood transfusions to maintain life life. Long term blood transfusion will cause heavy overload of iron load, so patients must be treated with iron removal. "According to the expected life expectancy of 40 years, each patient needs 4 million yuan cost, and each patient needs to spend 16000 ml of precious blood resources every year."." "Hematopoietic stem cell transplantation is currently the only effective cure method with beta thalassemia."   Li Chunfu, in thalassemia transplants, sibling transplants and unrelated transplantation cure rate is relatively high. In the South Hospital, especially in 2009, the cure rate of sibling transplantation and unrelated transplantation has reached over 90% after the transplantation technique was improved. "Before this, thalassemia patients transplantation is mainly transplantation and transplantation of unrelated compatriots."   Li Chunfu, and hematopoietic stem cell transplantation, and require donor bone marrow pairing must be completely consistent, called "identical", otherwise prone to rejection. However, the probability of matching perfectly, only identical twins is 100%, and unrelated population matched, the probability of only 1/100000. According to statistics, there are 34 thalassemia patients can not find a suitable bone marrow donor. To the south hospital as an example, as of the end of last month, in the hospital for pediatric transplant patients registered up to 3171 people, only 715 cases of successful pairing. Application: can be used for the treatment of childhood leukemia and aplastic anemia "it is worth mentioning that this" complementary transplantation technology "has also been applied in the treatment of children with leukemia and aplastic anemia and other diseases, also has obtained good curative effect."   Li Chunfu introduced, the application of this technology in the treatment of childhood leukemia, 30 patients, the cure rate was 64.3%, the overall survival rate was more than 70%. Especially 5 地贫移植供体不再难找 有血缘关系即可成供者   南方医院研发“半相合移植技术”还可应用于白血病治疗   黄蓉芳 准备做手术的小女孩。(资料图片)   广州日报记者苏俊杰摄   地贫患儿接受移植手术,再也不用担心找不到供体啦!昨日上午,记者从南方医科大学南方医院儿科召开的新闻发布会上获悉,该院的研究团队利用“半相合移植技术”,将跟患者有亲缘关系的“半相合供者”的造血干细胞与无关供者的脐血进行“互补性移植”,彻底解决了地贫移植的供者问题,治愈率高达96%。这一技术同样也适用于儿童白血病和再生障碍性贫血等疾病的治疗。只要是跟患者有亲缘关系的人,都可成为移植供者。    文 广州日报记者黄蓉芳   通讯员李晓姗   以前:3 4的患者找不到合适骨髓供者    南方医科大学南方医院儿科主任李春富介绍, 地中海贫血(简称地贫)多发于地中海沿岸,中东、中亚和东南亚等地区国家,我国以广东、广西和海南省发病率最高,其中重型β-地贫者须终生输血维持生命。而长期大量输血会使铁负荷严重超载,因此,患者必须进行祛铁治疗。“按预期寿命40年计算,每个病人需要400万元的花费,而且每个患者每年还需耗费16000毫升宝贵的血资源。”   “造血干细胞移植是目前唯一有效根治重型β-地贫的方法。” 李春富介绍,在地贫移植手术中,同胞移植和非亲缘移植治愈率比较高。   在南方医院,尤其是在2009年改良了移植技术之后,同胞移植和非亲缘移植治愈率已达90%以上。   “在此之前,地贫患者的移植主要是同胞移植和非亲缘移植手术。” 李春富介绍,而造血干细胞移植,均要求供者和受者的骨髓配对必须完全吻合,叫“全相合”,否则极易产生排异反应。然而,配对完全吻合的几率,只有同卵双生的双胞胎才是100%,而没有血缘关系人群,全相合的概率只有十万分之一。   据统计,有3 4的地贫患者找不到合适骨髓供者。以南方医院为例,截至上个月底,在该院儿科申请移植的注册病人高达3171人,配对成功的只有715例。   应用:可用于儿童白血病和再障治疗   “值得一提的是,这种‘互补性移植技术’也已应用在对儿童白血病和再生障碍性贫血等疾病的治疗中,也已经获得很好的疗效。” 李春富介绍,将这一技术应用对儿童白血病的治疗中,30例患者,治愈率为64.3%,总体生存率70%多。尤其是对于在移植前病情得到缓解的患者,治愈率达到了73%。   李春富介绍,利用这种互补性移植治疗地贫和白血病的两项成果,已分别被今年美国血液病协会年会确定为大会报告。“这就意味着这一移植技术已经达到国际领先水平。这使得所有地贫、儿童白血病以及再障等疾病患者,只要父母和其他亲属健在,都可以接受移植治疗。”   “解决了供者的难题,就意味着符合移植条件的患者大幅增加。”李春富说,但这也意味着,患者的待床期将更长了。因为医院的移植规模有限,很难及时为患者进行移植。   尽管南方医院儿童移植中心目前已是全球规模最大的地贫移植中心,但每年也只能完成80例地贫移植手术。“按传统的移植技术,目前配对成功的患者为715例,就算50%的病人到兄弟医院做移植,在南方医院儿科待床时间也长达4年多。”他说,如果利用新的技术,为要求移植的3171例患者做手术,患者的待床期就更长了。李春富呼吁,政府和社会共同创建一个更大规模的儿童移植中心。   如今:父母子女兄弟姐妹堂表亲都可当供者   李春富介绍,为了解决移植供者问题,南方医院儿科团队从2010年开始研究“半相合(父母)供者移植技术”,经历6年研究,创立了一个全新的移植概念:互补性移植(NF-CT-14-TM),即将跟患者有亲缘关系的“半相合供者”的造血干细胞与无关供者的脐血序贯移植,中间使用药物桥接,达到优势互补和双保险效果。   “我们这里虽然说的是父母,但其实凡是跟患者有血缘关系的亲属,都可以成为半相合供者。”李春富解释,按照遗传规律,人类的遗传基因一半来自父亲,另一半来自母亲,这就使得父母和孩子之间的染色体有一半是相吻合的。所谓“半相合”技术,在医学上叫做“单倍型相合骨髓移植”,只要求供髓者、受髓者之间的白细胞抗原一半相同就可以了,其实,这就意味着凡是有亲缘关系的父母、子女、兄弟姐妹,甚至堂表亲之间的骨髓都可进行半相合移植。   而南方医院儿科的“半相合(父母)供者移植技术”,将有亲缘关系的“半相合供者”的造血干细胞与无关供者的脐血结合了起来,相当于双次移植,“适者生存”,无论哪一种骨髓最后“胜利”,都可以成功。“而且,无关供者的脐血也无需完全配对,这就使得任何一个有亲属健在的患者,都不用再担心供者的问题。”   李春富介绍,从2014年到现在,已有31例地贫患者接受了该方案移植,除1例外,30例病人移植成功,治愈率高达96%。而且,伴有极少的严重排异反应,是目前全球记录的最好成绩。 责任编辑: GDN005相关的主题文章: